A novel coronavirus, SARS-CoV-2 (2019-nCoV) emerged in December 2019 as an immediate global
challenge. Comprehensive efforts at present time are focused simultaneously on containing spread of this virus and extenuating the ill effects. There is an immediate need for drugs that can help before a vaccine can be developed. Researchers are
endeavoring to find antiviral therapies specific to the virus. As the condition is an emerging, rapidly evolving situation
and development of new drugs is a long process, and is unfeasible to face the immediate global challenge. Strategy to reposition the previously used drugs can prove to be effective to combat this difficult to treat situation.
Several drugs such as Hydroxychloroquine, Umifenovir, Remdesivir, Lopinavir/Ritonavir, interferon, Darunavir,
Favipiravir, Nitazoxanide etc. are currently undergoing clinical studies to test the safety and efficacy of the drug
against this pandemic. The present review gives a snapshot look of the current clinical experience with repurposed antiviral